All issues
Volume 19 (2004)
- Issue 6 Pages 483-
- Issue 5 Pages 415-
- Issue 4 Pages 343-
- Issue 3 Pages 154-
- Issue 2 Pages 79-
- Issue 1 Pages 3-
Volume 19, Issue 6
Displaying 1-9 of 9 articles from this issue
- |<
- <
- 1
- >
- >|
-
Kazuo Maruyama2004 Volume 19 Issue 6 Pages 483
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSDownload PDF (240K) -
Shigeru Tsukagoshi2004 Volume 19 Issue 6 Pages 485
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSDownload PDF (216K) -
Anti-neovascular therapy by targeted liposomesTomohiro Asai, Naoto Oku2004 Volume 19 Issue 6 Pages 488-494
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSAntineovascular therapy aims to eradicate tumors by delivering cytotoxic agent to angiogenic vessels. The concept is different from tumor dormancy therapy by using angiogenesis inhibitors. For the purpose of antineovascular therapy, we isolated angiogenic vasculature-targeting peptide by a phage-displayed peptide library, and developed the peptide-modified liposomes. We demonstrated that the targeted liposomes containing cytotoxic agents effectively suppressed tumor growth through disrupting angiogenic vasculature. In this review, we summarize angiogenesis inhibitors, relationships between angiogenic vessels and liposomal anti-cancer agents, and usefulness of antineovascular therapy.View full abstractDownload PDF (1578K) -
Accelerated blood clearance of PEGylated liposomes after repeated injectionTatsuhiro Ishida, Hiroshi Kiwada2004 Volume 19 Issue 6 Pages 495-510
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSWe and a Dutch group have recently reported the accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes, that is the enhanced accumulation of PEGylated liposomes in liver and consequently rapidly cleared the liposomes from blood circulation. The phenomenon is a general characteristic of liposomes and the induction of the phenomenon depends on the physicochemical property and dose of liposomes and animal species. In addition, our study indicated that the IgM secreted in response to first dose is involved in the occurrence of the phenomenon. In this article, our and a Dutch group's recent results related to the ABC phenomenon were described.View full abstractDownload PDF (3728K) -
Polymer-coated liposomes for oral drug deliveryHirofumi Takeuchi2004 Volume 19 Issue 6 Pages 511-519
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSMucoadhesive liposomal systems were developed for oral delivery of poorly absorbable drugs such as peptide drugs. The novel drug delivery systems could be prepared by coating the surface of liposomes containing the drugs with mucoadhesive polymers such as chitosan and Carbopol. Improvement of peptide drug absorption with the polymer coated liposomes was demonstrated in rats. The penetration of the liposomal systems into the mucosa of rat intestines was observed with confocal laser scanning microscopy as well as their retentive properties in the intestinal tract. Immunological response was also detected in oral administration of the chitosan-coated liposomes containing ovalbumin.View full abstractDownload PDF (1973K) -
Research and development of immunoliposomesToshiaki Tagawa, Kazuhiro Takahashi2004 Volume 19 Issue 6 Pages 520-529
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSImmunoliposome, a type of liposome on which cancer cell specific antibody is conjugated, is expected as ideal drug delivery system which exhibits superior anticancer effect with lower side effect rather compared to conventional anticancer drugs owing to concentrating the drug or gene fragment onto cancer cells. In this article, we will show the result of non-clinical study focusing on the construction and the pharmacology of novel immunoliposorne, MCC-465, on which newly established human monoclonal antibody is conjugated. Furthermore, we will introduce the points which require special attention in developing the immunoliposome by discussing the result of first phase I clinical study of MCC-465.View full abstractDownload PDF (2261K) -
Liposomal formulation technology : in the case of preparation of liposornes for gene deliveryHiroshi Kikuchi2004 Volume 19 Issue 6 Pages 530-538
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSWhen the cationic liposomes containing DNA were prepared by the conventional lipid-film method, significant degradation and conformational change of DNA was observed during homogenization and sizing procedures, though DNA itself was relatively stable against these procedures. On the other band, when the freeze-dried empty liposomes (FDEL) method was used, no degradation, conformational change or loss of DNA was observed, and high transfection activity was obtained. These findings suggest that the FDEL method is very useful for preparation of liposomes containing DNA. If DNA/liposomes complex was formed using the commercialized cationic liposomes reagents, DNA was stable in the serum-containing medium but the structure of liposomes was disappeared. It was considered that this was the reason why serum-free medium had to be used for transfection. Among more than 300 formulations using the FDEL method, the novel cationic liposomes were developed which had higher transfection activity even in the serum-containing medium. In addition, the way of biodistribution control of cationic liposomes after intravenous administration is introduced in this paper.View full abstractDownload PDF (1901K) -
Immunoliposomes as druig delivery carrierRyo Suzuki, Tomoko Takizawa, Kazuo Maruyama2004 Volume 19 Issue 6 Pages 539-545
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSPolyethylene glycol derivatives containing liposomes (PEG-liposome) are expected to he useful drug delivery tools. Because they are not readily taken up by the reticulo-endothelial system (RES), stay in the circulation for a relatively long period of time and hence can effectively deliver anti-tumor drugs to the sites where have a high permeability of blood vessels such as tumor tissue. In the future, to improve safety and efficiency of liposome carrier, it is necessary for them to have a property of active targeting. From this point of view, the liposome, which was modified its surface with antibody for target molecule, was developed and it's called “immunoliposome”. It is an ideal drug carrier which has both properties of escaping RES and active targeting. Lately, the liposomes modified with proteins or peptides which recognize specific molecule as well as antibody were developed. In this review, we summarize about the liposomes as an active targeting carrier for tumor therapy.View full abstractDownload PDF (1556K) -
Shinsaku Nakagawa2004 Volume 19 Issue 6 Pages 546-549
Published: November 10, 2004
Released on J-STAGE: December 09, 2008
JOURNAL FREE ACCESSDownload PDF (814K)
- |<
- <
- 1
- >
- >|